New format to include original research articles
Beginning in 2011, Springer will publish Neurotherapeutics, the official Journal of the American Society for Experimental NeuroTherapeutics (ASENT). With the switch to Springer, Neurotherapeutics will change its format of publishing review articles only to offering original research articles as well. The journal achieved a debut Impact Factor of 5.38 in 2009, placing it in the top quartile of journals in both the Neurosciences and Pharmacology & Pharmacy categories.
Throughout its six-year history, Neurotherapeutics has exclusively published critical reviews in thematic, quarterly issues that highlight neurotherapeutics related to the clinical neurosciences. Each issue is developed by one or more distinguished guest editors who are expert in the topic area. The journal's editor-in-chief is Dr. Alan Faden, who directs the Shock Trauma and Anesthesiology Research (STAR) Center at the University of Maryland School of Medicine.
Springer will create a Neurotherapeutics portal and a page on the NeuroNetwork to promote themed issues, facilitate communication among the journal's readers, promote society news, and highlight both the preclinical and clinical articles in the journal through RSS feeds and podcasts.
Dr. Matthew Giampoala, Publishing Editor of Biomedicine at Springer, said, "We are very excited to be working with ASENT on this unique journal. No other journal is so thoughtfully bridging the gap between basic neuroscience and effective therapeutic breakthroughs. Springer and ASENT will work together to help the journal reach the widest possible audience."